Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
76
Akanda
AKAN
$3.41M
| $3.41M | $6.31 | 18.4% |
|
77
PRF Technologies Ltd
PRFX
$3.32M
| $3.32M | $1.09 | 4.39% |
|
|
SBFM
78
Sunshine Biopharma
SBFM
$3.25M
| $3.25M | $1.53 | 7.83% |
|
79
China SXT Pharmaceuticals
SXTC
$2.67M
| $2.67M | $0.0698 | 9.4% |
|
80
Universe Pharmaceuticals Inc
UPC
$2.24M
| $2.24M | $3.45 | 1.77% |
|
81
Shuttle Pharmaceuticals
SHPH
$1.71M
| $1.71M | $2.92 | 1.04% |
|
|
IMCC
82
IM Cannabis
IMCC
$968K
| $968K | $0.1074 | 11.2% |
|
|
TRUU
83
VanEck Utilities TruSector ETF
TRUU
$250K
| $250K | $24.95 | 1.38% |
|
Drug Manufacturers - Specialty & Generic Stocks at a Glance
Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.
There are 83 Drug Manufacturers - Specialty & Generic industry stocks tracked by Wall St. Rank, worth a combined $341B.
The largest by market cap are Takeda Pharmaceutical (TAK) at $55.7B, Haleon (HLN) at $43.8B and Teva Pharmaceuticals (TEVA) at $36.2B.
Among institutional investors, Amneal Pharmaceuticals (AMRX) drew the most net new fund positions in Q1 2026: 80 funds opened new positions, taking total fund holders up 39 (14%) quarter-over-quarter.
- Combined market cap: $341B across 83 stocks.
- Largest constituent: Takeda Pharmaceutical (TAK), $55.7B market cap.
- Most net new fund positions in Q1 2026: Amneal Pharmaceuticals (AMRX), +39 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.